Supportive treatment for cancer  Part 3
Authors: Eyssen Marijke , Benahmed Nadia , Desomer Anja 
Published: January 2025

APPENDIX REPORT 1 -- TABLE OF CONTENTS 1 -- LIST OF FIGURES 5 -- LIST OF TABLES 7 -- APPENDIX I 10 -- 1 SELECTION OF RELEVANT TOPICS BY EXTERNAL EXPERT PANEL 10 -- 1 1 ACCOMPANYING LETTER 10 -- 1 2 TABLE OF POSSIBLE TOPICS AND RESULT OF SELECTION BY EXPERTS 10 -- 1 3 DEFINITIONS OF PALLIATIVE CARE AND TERMINAL CARE 15 -- 2 QUALITY APPRAISAL INSTRUMENTS 16 -- 2 1 AMSTAR 16 -- 2 2 COCHRANE COLLABORATIONS TOOL FOR ASSESSING RISK OF BIAS 18 -- 3 SEARCH SYNTAX BY DATABASE 20 -- 3 1 SYSTEMATIC REVIEWS 20 -- 3 1 1 OVID Medline 20 -- 3 1 2 OVID PreMedline 21 -- 3 1 3 EMBASE 22 -- 3 1 4 Cochrane Library 23 -- 3 2 RANDOMIZED CONTROLLED TRIALS 24 -- 3 2 1 OVID Medline 24 -- 3 2 2 OVID PreMedline 26 -- 3 2 3 EMBASE 27 -- 3 2 4 CENTRAL 27 -- 4 SELECTION PROCESS 29 -- 4 1 RESULTS OF SELECTION PROCESS 29 -- 4 1 1 Guideline websites and websites of organisations in oncology 29 -- 4 2 SPECIFIC SELECTION CRITERIA 30 -- 4 2 1 Bisphosphonates 30 -- 5 MEASUREMENT INSTRUMENTS 33 -- 5 1 PAIN SCALES 33 -- 5 2 ANALGESIC USE MEASUREMENT 44 -- 5 3 PERFORMANCE STATUS SCALES 44 -- 5 4 QUALITY OF LIFE SCALES 46 -- 5 5 SUMMARY TABLE OF SCALES USED IN THIS REPORT 49 -- 6 COMPOSITION OF GUIDELINE DEVELOPMENT GROUP 51 -- 6 1 COMPOSITION OF THE PANEL OF EXTERNAL EXPERTS 51 -- 6 2 COMPOSITION OF THE STAKEHOLDER PANEL 51 -- 6 3 COMPOSITION OF THE KCE EXPERT TEAM 53 -- 6 4 COMPOSITION OF THE SCIENTIFIC VALIDATION TEAM 54 -- APPENDIX II 55 -- 1 QUALITY APPRAISAL 55 -- 1 1 GUIDELINES INCLUDING MULTIPLE TOPICS 55 -- 1 2 NSAIDS AND PARACETAMOL 56 -- 1 3 OPIOIDS 57 -- 1 4 CORTICOSTEROIDS 60 -- 2 GRADE PROFILES BY INTERVENTION AND OUTCOME 61 -- 2 1 NSAIDS AND PARACETAMOL 61 -- 2 2 OPIOIDS 67 -- 2 3 CORTICOSTEROIDS 79 -- 3 FOREST PLOTS 80 -- 3 1 NSAIDS AND PARACETAMOL 80 -- 3 2 OPIOIDS 80 -- 3 3 CORTICOSTEROIDS 80 -- 4 EVIDENCE TABLES 81 -- 4 1 NSAIDS AND PARACETAMOL 81 -- 4 2 OPIOIDS 91 -- 4 3 CORTICOSTEROIDS 144 -- 5 OVERVIEW OF INCLUDED AND EXCLUDED STUDIES 145 -- 5 1 OVERVIEW OF INCLUDED SRS 145 -- 5 2 OVERVIEW OF INCLUDED SRS FOUND BY HANDSEARCH 145 -- 5 3 OVERVIEW OF EXCLUDED SRS 145 -- 5 4 OVERVIEW OF INCLUDED RCTS 145 -- 5 5 OVERVIEW OF EXCLUDED RCTS 146 -- 6 EXAMPLE OF OPIOID EQUIANALGESIC TABLE 147 -- APPENDIX III 148 -- 1 QUALITY APPRAISAL 148 -- 1 1 GUIDELINES INCLUDING MULTIPLE TOPICS 148 -- 1 2 ANTIDEPRESSANTS 149 -- 1 3 ANTICONVULSANTS 151 -- 1 4 RADIOTHERAPY FOR PAINFUL BONE METASTASES 152 -- 1 5 RADIONUCLIDES FOR PAINFUL BONE METASTASES 154 -- 1 6 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 156 -- 1 7 CELIAC PLEXUS BLOCK 158 -- 2 GRADE PROFILES BY INTERVENTION AND OUTCOME 159 -- 2 1 ANTIDEPRESSANTS 159 -- 2 2 ANTICONVULSANTS 170 -- 2 3 RADIOTHERAPY FOR PAINFUL BONE METASTASES 179 -- 2 4 RADIONUCLIDES FOR PAINFUL BONE METASTASES 186 -- 2 5 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 190 -- 2 6 CELIAC PLEXUS BLOCK 208 -- 3 FOREST PLOTS 211 -- 3 1 RADIOTHERAPY FOR PAINFUL BONE METASTASES 211 -- 3 2 RADIONUCLIDES FOR PAINFUL BONE METASTASES 221 -- 3 2 1 Radionuclides versus placebo 221 -- 3 3 BISPHOSPHONATES FOR PAINFUL BONE METASTASES 230 -- 4 EVIDENCE TABLES 234 -- 4 1 ANTIDEPRESSANTS 234 -- 4 2 ANTICONVULSANTS 243 -- 4 3 RADIOTHERAPY FOR PAINFUL BONE METASTASES 264 -- 4 4 RADIONUCLIDES FOR PAINFUL BONE METASTASES 295 -- 4 5 BISPHOSPHANATES FOR PAINFUL BONE METASTASES 301 -- 4 6 CELIAC PLEXUS BLOCK 343 -- 5 OVERVIEW OF INCLUDED AND EXCLUDED STUDIES 351 -- 5 1 OVERVIEW OF INCLUDED SRS 351 -- 5 2 OVERVIEW OF INCLUDED SRS FOUND BY HANDSEARCH 351 -- 5 3 OVERVIEW OF EXCLUDED SRS 352 -- 5 4 OVERVIEW OF INCLUDED RCTS 352 -- 5 5 OVERVIEW OF EXCLUDED RCTS 353 -- APPENDIX IV 354 -- 1 CONSULTATION OF EXPERT PANEL 354 -- 2 CONSULTATION OF STAKEHOLDER PANEL 390 -- REFERENCES 411